Markets:

Overview

News

Currencies

International

Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

18.58 -0.24 (-1.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

January 17, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

January 15, 2025

From Zai Lab Limited

Via Business Wire

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

January 10, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Why Zai Lab (ZLAB) Stock Is Trading Higher ↗

November 15, 2024

Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering.

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

January 10, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

January 09, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Participation in Investor Conference in January 2025

December 12, 2024

From Zai Lab Limited

Via Business Wire

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? ↗

December 05, 2024

Via The Motley Fool

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients ↗

December 02, 2024

NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients.

Via Benzinga

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 02, 2024

From Zai Lab

Via Business Wire

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

November 27, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

November 21, 2024

From Zai Lab

Via Business Wire

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

November 18, 2024

From Zai Lab Limited

Via Business Wire

Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday ↗

November 15, 2024

Via Benzinga

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

November 14, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Proposed Public Offering of American Depositary Shares

November 13, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

November 12, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

November 11, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

October 29, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results ↗

October 24, 2024

The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells.

Via Investor's Business Daily

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday ↗

October 24, 2024

Via Benzinga

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

October 24, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Participation in November and December Investor Conferences

October 18, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

October 17, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

October 16, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

October 09, 2024

From Zai Lab Limited

Via Business Wire

Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 25, 2024

Via Benzinga

Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

September 17, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024

August 27, 2024

From Zai Lab Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.